Companies › Ranok Therapeutics (Hangzhou)
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RNK08954 KRAS G12D inhibitor | KRAS | Phase 2 | KRAS G12D Mutations | Nov 2026 |
| RNK08954-01 KRAS G12D inhibitor | KRAS | Phase 1 | KRAS G12D Mutation | Dec 2026 |
| RNK05047 Chaperone-mediated protein degrader | – | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05487170 | RNK05047 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2025 |
| NCT07303465 | RNK08954 | Phase 2 | KRAS G12D Mutations | Oncology | Nov 2026 |
| NCT06667544 | RNK08954-01 | Phase 1 | KRAS G12D Mutation | Other | Dec 2026 |
Kumquat Biosciences Genfleet Therapeutics (Shanghai) Jacobio Pharmaceuticals Abbisko Therapeutics HUYABIO International
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.